J Rieber1,2, E Tonndorf-Martini1,2, O Schramm1,2, B Rhein1,2, S Stefanowicz1,2, J Kappes3,4,5, H Hoffmann3,6,5, K Lindel1,2, J Debus1,2, S Rieken7,8. 1. Department of Radiation Oncology, University Hospital Heidelberg, INF 400, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. 2. Heidelberg Institute of Radiation Oncology, Heidelberg, Germany. 3. Translational Research Unit, Thoraxklinik, Heidelberg University, Heidelberg, Germany. 4. Department of Pneumology, Thoraxklinik, Heidelberg University, Heidelberg, Germany. 5. Translational Lung Research Centre Heidelberg (TLRC-H), Member of the German Centre for Lung Research (DZL), Heidelberg, Germany. 6. Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Heidelberg, Germany. 7. Department of Radiation Oncology, University Hospital Heidelberg, INF 400, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. stefan.rieken@med.uni-heidelberg.de. 8. Heidelberg Institute of Radiation Oncology, Heidelberg, Germany. stefan.rieken@med.uni-heidelberg.de.
Abstract
BACKGROUND: Radiosurgical treatment of brain metastases is well established in daily clinical routine. Utilization of flattening-filter-free beams (FFF) may allow for more rapid delivery of treatment doses and improve clinical comfort. Hence, we compared plan quality and efficiency of radiosurgery in FFF mode to FF techniques. MATERIALS AND METHODS: Between November 2014 and June 2015, 21 consecutive patients with 25 brain metastases were treated with stereotactic radiosurgery (SRS) in FFF mode. Brain metastases received dose-fractionation schedules of 1 × 20 Gy or 1 × 18 Gy, delivered to the conformally enclosing 80 % isodose. Three patients with critically localized or large (>3 cm) brain metastases were treated with 6 × 5 Gy. Plan quality and efficiency were evaluated by analyzing conformity, dose gradients, dose to healthy brain tissue, treatment delivery time, and number of monitor units. FFF plans were compared to those using the FF method, and early clinical outcome and toxicity were assessed. RESULTS: FFF mode resulted in significant reductions in beam-on time (p < 0.001) and mean brain dose (p = 0.001) relative to FF-mode comparison plans. Furthermore, significant improvements in dose gradients and sharper dose falloffs were found for SRS in FFF mode (-1.1 %, -29.6 %; p ≤ 0.003), but conformity was slightly superior in SRS in FF mode (-1.3 %; p = 0.001). With a median follow-up time of 5.1 months, 6‑month overall survival was 63.3 %. Local control was observed in 24 of 25 brain metastases (96 %). CONCLUSION: SRS in FFF mode is time efficient and provides similar plan quality with the opportunity of slightly reduced dose exposure to healthy brain tissue when compared to SRS in FF mode. Clinical outcomes appear promising and show only modest treatment-related toxicity.
BACKGROUND: Radiosurgical treatment of brain metastases is well established in daily clinical routine. Utilization of flattening-filter-free beams (FFF) may allow for more rapid delivery of treatment doses and improve clinical comfort. Hence, we compared plan quality and efficiency of radiosurgery in FFF mode to FF techniques. MATERIALS AND METHODS: Between November 2014 and June 2015, 21 consecutive patients with 25 brain metastases were treated with stereotactic radiosurgery (SRS) in FFF mode. Brain metastases received dose-fractionation schedules of 1 × 20 Gy or 1 × 18 Gy, delivered to the conformally enclosing 80 % isodose. Three patients with critically localized or large (>3 cm) brain metastases were treated with 6 × 5 Gy. Plan quality and efficiency were evaluated by analyzing conformity, dose gradients, dose to healthy brain tissue, treatment delivery time, and number of monitor units. FFF plans were compared to those using the FF method, and early clinical outcome and toxicity were assessed. RESULTS: FFF mode resulted in significant reductions in beam-on time (p < 0.001) and mean brain dose (p = 0.001) relative to FF-mode comparison plans. Furthermore, significant improvements in dose gradients and sharper dose falloffs were found for SRS in FFF mode (-1.1 %, -29.6 %; p ≤ 0.003), but conformity was slightly superior in SRS in FF mode (-1.3 %; p = 0.001). With a median follow-up time of 5.1 months, 6‑month overall survival was 63.3 %. Local control was observed in 24 of 25 brain metastases (96 %). CONCLUSION:SRS in FFF mode is time efficient and provides similar plan quality with the opportunity of slightly reduced dose exposure to healthy brain tissue when compared to SRS in FF mode. Clinical outcomes appear promising and show only modest treatment-related toxicity.
Entities:
Keywords:
Brain metastases; Flattening-filter free; Plan comparison; Radiosurgery; Stereotactic radiotherapy
Authors: Kees H Spruijt; Max Dahele; Johan P Cuijpers; Marloes Jeulink; Derek Rietveld; Ben J Slotman; Wilko F A R Verbakel Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-05 Impact factor: 7.038
Authors: Martin Kocher; Andrea Wittig; Marc Dieter Piroth; Harald Treuer; Heinrich Seegenschmiedt; Maximilian Ruge; Anca-Ligia Grosu; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2014-04-09 Impact factor: 3.621
Authors: Dirk Rades; Dagmar Hornung; Oliver Blanck; Kristina Martens; Mai Trong Khoa; Ngo Thuy Trang; Michael Hüppe; Patrick Terheyden; Jan Gliemroth; Steven E Schild Journal: Strahlenther Onkol Date: 2014-03-25 Impact factor: 3.621
Authors: Daniel R Zwahlen; Stephanie Lang; Jan Hrbacek; Christoph Glanzmann; Stephan Kloeck; Yousef Najafi; Tino Streller; Gabriela Studer; Kathrin Zaugg; Urs M Luetolf Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-07 Impact factor: 7.038
Authors: Rami A El Shafie; Eric Tonndorf-Martini; Daniela Schmitt; Aylin Celik; Dorothea Weber; Kristin Lang; Laila König; Simon Höne; Tobias Forster; Bastian von Nettelbladt; Sebastian Adeberg; Jürgen Debus; Stefan Rieken; Denise Bernhardt Journal: Front Oncol Date: 2020-05-08 Impact factor: 6.244